MARKET SHARE AND SWITCHING DYNAMICS BETWEEN ETANERCEPT AND ITS BIOSIMILAR PRODUCT IN SWEDEN AND GERMANY- A REAL-WORLD PRELIMINARY ANALYSIS
Author(s)
Alten R1, Neregård P2, Jones HE3, Meng T4, Curiale C5, Singh E6, Lucchese L7, Gossen N8, Bergman GJ9, Miglio C7
1Shlosspark-Klinik Teaching Hospital of the Charité, Berlin, Germany, 2Pfizer, Sollentuna, Sweden, 3Pfizer inc., Collegeville, PA, USA, 4Pfizer Pharma GmbH, Berlin, Germany, 5Pfizer, Rome, Italy, 6Pfizer Inc., Collegeville, PA, USA, 7QuintilesIMS, London, UK, 8QuintilesIMS, Frankfurt, Germany, 9QuintilesIMS, Solna, Sweden
OBJECTIVES: To describe the market share and switching dynamics between etanercept innovator (EtnI) and its biosimilar (EtnBS) indicated for rheumatic diseases, in Germany and Sweden. METHODS: Patients receiving rheumatologists’ prescriptions for EtnI and EtnBS in November 2015-March 217 were retrospectively identified using the Swedish Prescription Registry (100% of retail biologic prescriptions) and the QuintilesIMS® German Longitudinal Prescriptions database (LRx, RESULTS: Both in Germany and Sweden, the market share of EtnI constantly decreased and that of EtnBS constantly increased after EtnBS was launched. In the month of launch (Germany: February 2016; Sweden: April 2016), the proportion of patients who switched to EtnBS from any biologic treatment was ~100% in Germany and only 22% in Sweden. In the most recent 6 months, this proportion ranged from 41% to 49% in Germany and from 61% to 72% in Sweden. In both countries there was a similar proportion of patients with prior EtnI who switched back to the original EtnI (10% in Germany and 11% in Sweden) or any biologic agents (14% in both countries) after only 75 (Germany) and 55 (Sweden) days of treatment with EtnBS. CONCLUSIONS: Despite the observed differences in market penetration, we found that both in Germany and Sweden there is a proportion of patients who switch back to the original biologic agent after being moved to EtnBS. Future studies should confirm these results and investigate the reasons for changing back to original biologics.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PSY120
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior
Disease
Systemic Disorders/Conditions